Ahmed Khan, MD
Pulmonary Disease · Schenectady, NYNPI 1881870178
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Pulmonx Corporation at 34.4% of the total. Reporting peaked in 2024 at $10,131 and has fallen 66.8% since, to $3,363 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $67.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$8K
- AstraZeneca$4K
- Intuitive Surgical$4K
- GSK$2K
- Johnson & Johnson$1K
- Medical Device Business Services, Inc.$936
- plus $3K from 33 others
Across 72 payments — averaging $5955.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$216K
- AstraZeneca$134K
- Mylan Specialty L.p.$59K
- GSK$19K
- Eli Lilly$951
What the payments were for
- Consulting fees$5,00020%
- Speaking & faculty fees$4,97520%
- Travel & lodging$4,84420%
- Food & beverage$8,25333%
- Education$1,5416%
- Gifts$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 12 | $8,470 |
| AstraZeneca | 50 | $4,245 |
| Intuitive Surgical | 10 | $4,039 |
| GSK | 114 | $1,987 |
| Johnson & Johnson(2 entities) | 19 | $1,471 |
| Medical Device Business Services, Inc. | 8 | $936 |
| Boehringer Ingelheim | 17 | $359 |
| AbbVie | 17 | $353 |
| Novartis | 14 | $316 |
| Harmony Biosciences LLC | 11 | $267 |
| Regeneron Healthcare Solutions, Inc. | 7 | $208 |
| Amgen(2 entities) | 9 | $192 |
| Philips North America LLC | 9 | $172 |
| Genentech USA, Inc. | 9 | $156 |
| Pfizer | 7 | $156 |
| Sanofi | 5 | $125 |
| Inspire Medical Systems, Inc. | 1 | $119 |
| Verona Pharma, Inc. | 4 | $113 |
| Si-bone, Inc. | 1 | $112 |
| Electromed, Inc. | 6 | $111 |
| Galvanize Therapeutics, Inc | 1 | $107 |
| Merck | 4 | $80 |
| Chiesi USA, Inc. | 3 | $75 |
| Grifols USA, LLC | 3 | $68 |
| Insmed, Inc. | 3 | $59 |
| Astellas Pharma US Inc | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $45 |
| Shionogi Inc | 2 | $42 |
| United Therapeutics Corporation | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Baxter Healthcare | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Vapotherm Inc | 1 | $14 |
| Veran Medical Technologies, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
| Shockwave Medical, Inc | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,646 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 308 | $433,140 |
| Breo ElliptaFluticasone/Vilanterol | 132 | $120,337 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $117,540 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $62,461 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $47,889 |
| Dupixent PenDupilumab | 12 | $43,420 |
| EliquisApixaban | 32 | $37,094 |
| Spiriva RespimatTiotropium Bromide | 26 | $29,187 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $26,853 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $19,297 |
| XareltoRivaroxaban | 19 | $18,565 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $13,090 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $11,668 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 287 | $11,045 |
| Roflumilast | 29 | $7,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,987 | $642,791543 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,245 | $60,97972 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $359 | $48,48350 claims |
| PfizerEliquis | $156 | $37,09432 claims |
| Johnson & JohnsonXarelto | $1,471 | $18,56519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Schenectady
- Jehanzeb KhanSchenectady$56K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.